3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Sarcoma
3
Wilms Tumor
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Ovarian Neoplasms
1
Neoplasms
1
Histiocytic Sarcoma
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
12
Pemetrexed
9
Cisplatin
9
Nivolumab
8
Carboplatin
8
Ipilimumab
7
Cyclophosphamide
6
fludarabine
5
durvalumab
4
tremelimumab
2
Radiotherapy, Intensity-Modulated
2
Gemcitabine
2
Cerebral Decortication
2
tocilizumab
1
tislelizumab
1
tazemetostat
1
sotorasib
1
ruxolitinib
1
osimertinib
1
olaparib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
bintrafusp alfa protein, human
1
avelumab
1
atezolizumab
1
Tumor Burden
1
Temozolomide
1
Tablets
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma
×
LY3023414
×
1 year
×
Clear all
No trials found.